Chronic GVHD Treatment Overview: Immunosuppressives, New Agents, and What Patients Need to Know
Panelists discuss how the current treatment landscape for chronic graft-versus-host disease includes a range of immunosuppressive approaches, from traditional corticosteroids and calcineurin inhibitors to newer approved agents like axatilimab, ruxolitinib, belumosudil, ibrutinib, and abatacept, emphasizing key considerations patients should be aware of when undergoing these therapies.
EP: 1.Chronic Graft-versus-Host Disease: Understanding the Disease and Its Widespread Symptoms
EP: 2.Comprehensive Patient Education and Symptom Awareness with GVHD
EP: 3.Managing Severe Symptoms and Disease Progression in the GVHD Journey
EP: 4.Early Symptom Detection and the Impact on Patient Outcomes in GVHD
EP: 5.Patient Communication and Collaborative Care for Symptom Management
EP: 6.Chronic GVHD Treatment Overview: Immunosuppressives, New Agents, and What Patients Need to Know
Video content above is prompted by the following:
Let's discuss the current treatment landscape for cGVHD, including emerging therapies and their potential impact on patient care.
- Can you provide an overview of the current treatment approaches for cGVHD? Please highlight GVHD management relies on immunosuppressive treatments like corticosteroids, calcineurin inhibitors, and monoclonal antibodies. Several agents have been approved for various GVHD settings, including axatilimab, ruxolitinib, belumosudil, ibrutinib, and abatacept.
- What key things should patients be aware of when receiving therapies?
BLA Resubmission Accepted by the FDA for Remestemcel-L in Pediatric Steroid-Refractory aGVHD
August 11th 2024The biologics license application that was resubmitted for remestemcel-L has been accepted by the FDA for the potential treatment of children with steroid-refractory acute graft-vs-host-disease.
